Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Retained Earnings data on record, last reported at $186000.0 in Q3 2025.

  • For Q3 2025, Retained Earnings fell 88.33% year-over-year to $186000.0; the TTM value through Sep 2025 reached $186000.0, down 88.33%, while the annual FY2024 figure was -$1.1 billion, 48158.11% down from the prior year.
  • Retained Earnings reached $186000.0 in Q3 2025 per ZNTL's latest filing, up from -$1.1 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.2 million in Q4 2023 and bottomed at -$1.1 billion in Q2 2025.
  • Average Retained Earnings over 4 years is -$461.3 million, with a median of -$418.6 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: surged 262.16% in 2023, then plummeted 285925.15% in 2024.
  • A 4-year view of Retained Earnings shows it stood at -$1.4 million in 2022, then soared by 262.16% to $2.2 million in 2023, then tumbled by 48158.11% to -$1.1 billion in 2024, then surged by 100.02% to $186000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $186000.0 in Q3 2025, -$1.1 billion in Q2 2025, and -$1.1 billion in Q1 2025.